View from inside

Welcome to the Scrip World Pharmaceutical News editorial blog, View from inside.

Read the Scrip teams views on the hottest topics in the vibrant world of pharmaceutical news and make your opinions known.

Merck & Co underlines pharma’s resilience to recession

The news that grabbed the headlines last week was Merck & Co’s aim to lead generic biologics. As it stands, Merck could be the first US brand name drug company to enter the generic biologics market...
Read More

Posted 18/12/2008 15:59:45 PM
by Christopher Spillane,
Reporter

The 'truth drug'

The Indian authorities are reported to be using a so-called ‘truth drug’ on the man arrested on suspicion of involvement in the recent atrocities in Mumbai.
Read More

Posted 11/12/2008 17:12:00 PM
by Dr Peter Charlish,
Analyst

A personal brush with generics in Japan

The occasion of a recent family visit to the doctor gave a small but revealing insight into how things are changing in Japan's evolving but potentially huge market for generic drugs.
Read More

Posted 11/12/2008 16:58:34 PM
by Ian Haydock,
Asia Editor

MicroRNA – a technology to rival RNAi?

One of the hot topics in drug discovery at the moment is microRNA (miRNA). MicroRNAs are short pieces of single-stranded RNA, about 21-23 bases long, that bind to matching sequences of messenger RNA, thereby rendering them double-stranded and inhibiting the production of the corresponding protein.
Read More

Posted 01/12/2008 15:43:18 PM
by Dr Peter Charlish,
Analyst

Sir Alan Sugar's firm targets messages to doctors' waiting rooms

Doctors waiting rooms full of nervous patients are soulless places, but their mood may soon be lightened in the UK by digital screens displaying health messages from Amscreen Healthcare, a new digital signage company from the well-known serial UK entrepreneur and TV personality, Sir Alan Sugar.
Read More

Posted 01/12/2008 10:55:31 AM
by John Davis,
Managing Editor

MAbs – what’s in a name?

Ever wondered how those weird names for antibody-based products are dreamed up? Rituximab, trastuzumab, infliximab – there’s obviously a scheme behind the naming of MAbs, but just what is it?
Read More

Posted 28/11/2008 16:01:00 PM
by Dr Peter Charlish,
Analyst

New tool for vaccine development

One of the challenges of developing a new vaccine is to determine just how immunogenic it is and how long the protection it offers will persist. Now at last an answer to this problem may be at hand.
Read More

Posted 26/11/2008 17:09:11 PM
by Dr Peter Charlish,
Analyst

US post-election buzz: a tale of stem cells, trade agreements and power struggles

One week after US voters elected Illinois Democratic senator Barack Obama as their next president, we offer a few interesting post-election tidbits on which Scrip's Washington bureau is keeping an eye (and that don't involve use of a crystal ball or an Ouija board to divine the name of the next FDA commissioner).
Read More

Posted 11/11/2008 12:54:35 PM
by Sue Sutter,
Washington Editor

There's no ignoring a meta-analysis

Pharmaceutical companies should proceed with great care in deciding whether to conduct a meta-analysis, and the results should be used "ever so cautiously, if at all, in making decisions", a former industry exec believes.
Read More

Posted 27/10/2008 15:36:23 PM
by Sue Sutter,
Washington Editor

New US FDAAA law not a burden for pharma

The industry’s fears that they would be swamped with labelling changes, demands for postmarketing studies and risk analyses under the FDA Amendments Act have not been realised.
Read More

Posted 16/10/2008 16:39:18 PM
by Sue Sutter,
Washington Editor

Previous 1 Next